**Core Concept:** Teicoplanin is a glycopeptide antibiotic used for treating severe infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA). Quinine is an antimalarial drug used in the treatment of Plasmodium falciparum malaria.

**Why the Correct Answer is Right:** Teicoplanin is not the correct treatment for malaria as it is a glycopeptide antibiotic. Quinine is the preferred treatment for severe malaria due to its ability to cross the blood-brain barrier, effectively reducing parasitemia and alleviating symptoms. In contrast, teicoplanin is specific to Gram-positive bacteria and lacks antimalarial properties.

**Why Each Wrong Option is Incorrect:**

A. Chloroquine: An antimalarial drug primarily used for the treatment of Plasmodium vivax and Plasmodium ovale malaria. It is not suitable for treating severe malaria caused by P. falciparum due to its resistance.

B. Artemisinin-based combination therapy (ACT): This option is irrelevant because ACT is a combination of antimalarial drugs, typically artemisinin and a partner drug, used to treat uncomplicated P. falciparum malaria. It is not suitable for treating severe malaria.

C. Penicillin: A beta-lactam antibiotic specific to Gram-positive bacteria and not effective against Plasmodium parasites.

D. Ceftriaxone: A third-generation cephalosporin antibiotic effective against Gram-negative bacteria and not suitable for treating severe malaria caused by P. falciparum due to its specificity for Gram-negative bacteria.

**Clinical Pearl:** In cases of severe malaria, prompt initiation of appropriate antimalarial treatment, such as quinine, is essential to reduce mortality and improve patient outcomes. Quinine therapy should be combined with supportive care, including fluid replacement, correction of electrolyte imbalances, and management of complications.